The studies exploring the mechanisms behind body mass reduction obtained using GLP-1 receptor agonists identified hypothalamic sites of action for this class of drugs, and our results may expand the knowledge about the central actions of liraglutide, semaglutide and the new single-, dual-, and triple-agonists entering the market for treating patients with obesity [30–32]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.